Exosomal long noncoding RNA lnc-GNAQ-6:1 may serve as a diagnostic marker for gastric cancer

Li, Shibao; Zhang, Miaomiao; Zhang, Haoliang; Hu, Kan; Cai, Chenchen; Wang, Jiwei; Shi, Lubin; Ma, Ping; Xu, Yinhai; Zheng, Peiming

doi:10.1016/j.cca.2019.10.047

Cited by 58 publications

(32 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In current years, multi-omics have developed rapidly with the application of high-throughput screening. Long non-coding RNA has drawn widespread attention as a prospective molecular target for cancer diagnosis and therapeutics [36][37][38]. Several studies have proposed that lncRNAs were involved in the immune process contributed to tumorigenesis and progression [39][40][41].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of an immune long non-coding RNA signature in liver hepatocellular carcinoma

Kong

Wang

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: In recent years, long non-coding RNAs (lncRNAs) are emerging as crucial regulators in the immunological process of liver hepatocellular carcinoma (LIHC). Increasing studies have found that some lncRNAs could be used as a diagnostic or therapeutic target for clinical management, but little research has investigated the role of immune-related lncRNA in tumor prognosis. In this study, we aimed to develop an immune lncRNA signature for the precise diagnosis and prognosis of liver hepatocellular carcinoma. Methods: Gene expression profiles of LIHC samples obtained from TCGA were screened for immune-related genes using two reference gene sets. The optimal immune-related lncRNA signature was built via correlational analysis, univariate and multivariate cox analysis. Then the Kaplan-Meier plot, ROC curve, clinical analysis, gene set enrichment analysis, and principal component analysis were carried out to evaluate the capability of immune lncRNA signature as a prognostic indicator. Results: Six long non-coding RNA MSC−AS1, AC009005.1, AL117336.3, AL031985.3, AL365203.2, AC099850.3 were identified via correlation analysis and cox regression analysis considering their interactions with immune genes. Next, tumor samples were separated into two risk groups by the signature with different clinical outcomes. Stratification analysis showed the prognostic ability of this signature acted as an independent factor. The AUC value of ROC curve was 0.779. The Kaplan-Meier method was used in survival analysis and results showed a statistical difference between the two risk groups. The predictive performance of this signature was validated by principal component analysis (PCA). Data from gene set enrichment analysis (GSEA) further unveiled several potential biological processes of these biomarkers may involve in. Conclusion: In summary, the study demonstrated the potential role of the six-lncRNA signature served as an independent prognostic factor for LIHC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of an immune long non-coding RNA signature in liver hepatocellular carcinoma

Kong

Wang

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…The levels of carcinoembryonic antigen (CEA), cancer antigen (CA)242, CA199 and CA153 in serum were determined by an immunoassay analyzer (Cobas E602, Roche Diagnostics, Indianapolis, Indiana, USA) in accordance with previous literature [ 17 ].…”

Section: Methodsmentioning

confidence: 99%

Extracellular Vesicle-Transported Long Non-Coding RNA (LncRNA) X Inactive-Specific Transcript (XIST) in Serum is a Potential Novel Biomarker for Colorectal Cancer Diagnosis

Dong

Liang

2020

Med Sci Monit

View full text Add to dashboard Cite

“…For instance, the expression of serum exosomal lncRNA PCSK2‐2:1 was significantly reduced in patients with GC, and downregulation of serum exosomal lncRNA PCSK2‐2:1 was associated with adverse clinical parameters of GC 13 . Similarly, serum exosomal lnc‐GNAQ‐6:1 level was lower in GC patients and exhibited good performance for discriminating GC patients from healthy volunteers 14 …”

Section: Introductionmentioning

confidence: 97%

“…13 Similarly, serum exosomal lnc-GNAQ-6:1 level was lower in GC patients and exhibited good performance for discriminating GC patients from healthy volunteers. 14 Myocardial infarction associated transcript (MIAT) was first identified as a lncRNA in 2006 and mapped to human chromosome 12q12.1. 15 MIAT was upregulated both in GC tissues and cell lines.…”

mentioning

confidence: 99%

Identification of serum exosomal lncRNA MIAT as a novel diagnostic and prognostic biomarker for gastric cancer

Zhou

Tang

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Accumulating evidence has demonstrated that long non‐coding RNAs (lncRNAs) MIAT is significantly upregulated in many cancer types including gastric cancer (GC). However, the potential clinical significance of serum exosomal MIAT in GC is unknown. Methods In this study, a total of 109 GC patients, 48 gastric adenoma patients, and 50 healthy individuals were recruited. Serum exosomal MIAT levels were detected in all participants using quantitative real‐time reverse transcription‐polymerase chain reaction (qRT‐PCR). Results The exosomes we extracted from the serum samples were positive for TSG101, CD63, and Flotillin‐1, which were known exosome markers. Serum exosomal MIAT levels were significantly higher in GC patients than in gastric adenoma patients and healthy controls. Interestingly, gastric adenoma patients with higher serum exosomal MIAT expression were more prone to develop GC. In addition, serum exosomal MIAT levels were significantly decreased in post‐treatment blood samples compared to pre‐treatment samples, while markedly increased in the cases suffering recurrence. Moreover, serum exosomal MIAT upregulation was significantly associated with worse clinical variables and shorter survival. Furthermore, serum exosomal MIAT was identified as an independent prognostic factor for GC. Conclusions Collectively, serum exosomal lncRNA MIAT might serve as a promising novel biomarker for monitoring the progression of GC.

show abstract

Exosomal long noncoding RNA lnc-GNAQ-6:1 may serve as a diagnostic marker for gastric cancer

Cited by 58 publications

References 37 publications

Prognostic value of an immune long non-coding RNA signature in liver hepatocellular carcinoma

Prognostic value of an immune long non-coding RNA signature in liver hepatocellular carcinoma

Extracellular Vesicle-Transported Long Non-Coding RNA (LncRNA) X Inactive-Specific Transcript (XIST) in Serum is a Potential Novel Biomarker for Colorectal Cancer Diagnosis

Identification of serum exosomal lncRNA MIAT as a novel diagnostic and prognostic biomarker for gastric cancer

Contact Info

Product

Resources

About